Clinical Trials Market By Phases (Phase I, Phase II, Phase III, and Other), By Study Design (Interventional Trials, Observational Trials, and Other), By Indications/Symptoms (Cancer, Circulatory, CNS, and Others) and Region - Global Forecast to 2028
-
317
-
April 2018
-
195
-
PDF
-
-
Request for Sample
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
-
The Clinical Trials Market is segmented on the basis of phases, study design, indications/symptoms, and region.
Global Clinical Trials Market: Overview
The clinical Trials Market was valued at $24 million in 2020 & is projected to reach $34 million by 2030. It is expected to grow at a 5% CAGR between 2021 and 2030.
Clinical trials are types of research studies, conducted on individuals who volunteered for testing medical equipment or drugs in order to determine treatment for certain diseases or disorders.
They are conducted in order to diagnose, detect, and prevent various types of diseases. Each clinical trials have certain protocols and action plan to execute the testing procedure.
Clinical trials help to generate data regarding the efficiency, effectiveness, and safety of drugs and medical treatments on animals and humans.
Global Clinical Trials Market: Dynamics
Increasing demand for new medical equipment and medicines among end-users, coupled with growing investment in research and development activities for the development of effective medicines are major factors driving the growth of the global clinical trials market.
In addition, the increasing number of individuals suffering from chronic diseases as well as changing conditions and the nature of certain types of chronic diseases is another factor anticipated to support the growth of the global clinical trials market to a significant extent.
Furthermore, the increasing prevalence of neurological diseases such as Parkinson’s, Alzheimer’s, tumors, depression, and epilepsy, coupled with the growing geriatric population are also factors expected to drive the growth of the target market over the forecast period.
Increasing clinical trials for finding effective and permanent solutions to cure or slow down and prevent the spread of neurological diseases and aging diseases is a factor propelling the growth of the target market.
Moreover, occurrence of tropical and infectious diseases, that require new medicines and drugs in various countries is a factor expected to support growth of the target market over the forecast period.
Furthermore, the digitalization of clinical trials in order to enhance productivity and gather data from multiple sources is a factor expected to boost the growth of the global market in the near future.
However, regulations regarding conducting clinical trials on individuals are expected to hamper the growth of the target market.
In addition, clinical trials are costly and their cost differs from each phase of the test is another factor that could affect the growth of the global market.
Moreover, increasing adoption of virtual clinical trials in which data can be gathered efficiently and safely from participants without the requirement of traveling to the lab or office of the doctor.
In this method, warble and mobile devices are used for monitoring and data gathering regarding condition of the individual is a factor expected to create opportunities for the players in the target market.
Global Clinical Trials Market Analysis by Phases
Among the phase segments, the phase II segment is expected to account for a major revenue share and is expected to maintain its dominance over the forecast period.
The phase II segment is expected to register a CAGR of over 5.8%, as it is conducted for safety and efficiency.
The phase III segment accounts for the second-highest share in terms of revenue in the near future. Phase III is conducted for confirmation regarding completion or termination of trial.
Global Clinical Trials Market Analysis by Study Design
Currently, among the study design segments, the interventional trials segment accounts for a major revenue share and is expected to maintain its dominance over the forecast period.
The interventional trials segment is expected to register a CAGR of over 5.5%, owing to evolution and innovation in the treatment is expected to support revenue growth of this segment in the global market.
The interventional trials segment is also anticipated to witness the highest growth in terms of revenue in the near future.
Global Clinical Trials Market Analysis by Indications/Symptoms
Among the indications/symptoms segments, the cancer segment is expected to account for a significant share in terms of revenue and is expected to maintain its position over the forecast period.
The cancer segment is expected to register a CAGR of over 6%, owing to the increasing number of individuals suffering from different types of cancers is expected to support revenue growth of this segment in the target market.
The others segments are expected to account for the second-highest share in terms of revenue in the near future.
Global Clinical Trials Market Analysis by Region
Currently, the market in North America is dominating the global market in terms of revenue and is expected to maintain its dominance over the forecast period.
The presence of prominent pharmaceutical manufacturing companies, coupled with increasing investment in the development of new medicines are major factors driving the growth of the clinical trials market in North America.
The market in Europe accounts for the second-highest share in terms of revenue and is expected to register lucrative growth in the near future.
Government support for research and development for treatment and medicines for emerging infectious diseases as well as chronic diseases, especially in countries such as the UK and Germany is a major factor fueling the growth of the target market in this region.
In addition, the presence of key players and a favorable environment for conducting clinical trials is another factor expected to support the growth of the clinical trial market in Europe over the forecast period.
Market in the Asia Pacific is expected to register the fastest growth in terms of revenue in the near future. Increasing demand for medical drugs and devices, owing to the increasing number of individuals suffering from cardiovascular diseases, cancer, and obesity is a factor supporting the growth of the target market in this region.
Additionally, the increasing number of healthcare facilities, coupled with investment by government and private sectors in order to provide medicines and medical treatment at an affordable cost are factors anticipated to support the growth of the clinical trial market in the Asia Pacific market over the forecast period.
Furthermore, the growing geriatric population in countries in this region such as Japan and China, as well as the rising prevalence of age-related diseases among individuals are factors propelling the growth of the target market.
Market in Middle East & Africa is expected to witness lucrative growth in terms of revenue over the forecast period, followed by Latin America.
Increasing government investment in the development of technologically advanced medical facilities in the United Arab Emirates and Saudi Arabia is a factor expected to support the growth of the clinical trial market in the Middle East & Africa region.
In addition, government initiatives to create significant revenue growth opportunities in this region are another factor anticipated to support the growth of the target market in this region.
Global Clinical Trials Market Segmentation:
Global Clinical Trials Market Segmentation, by Phases:
- Phase I
- Phase II
- Phase III
- Phase IV
Global Clinical Trials Market Segmentation, by Study Design:
- Interventional Trials
- Observational Trials
- Expanded Access Trials
Global Clinical Trials Market Segmentation, by Indications/Symptoms:
- Autoimmune
- Blood Disorders
- Cancer
- Circulatory
- CNS
- Congenital
- CVS
- Dermatology
- Ear
- Gastrointestinal
- Genitourinary
- Infections
- Mental Disorders
- Metabolic
- Musculoskeletal
- Nose
- Ophthalmology
- Others (Egg Freezing, Sperm Freezing, and Embryo Freezing)
Global Clinical Trials Market Segmentation, by Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn -
- Eli Lilly and Company
- Sun Pharmaceutical Industries Ltd.
- Novo Nordisk A/S
- Pfizer Inc.
- ICON plc
- Sanofi
- Laboratory Corporation of America Holdings
- Hoffmann-La Roche Ltd.
- PAREXEL International Corporation
- IQVIA Holdings Inc.
-
- 1 Chapter 1
- 1.1 Preface
- 1.2 Assumptions
- 1.3 Abbreviations
- 2 Chapter 2
- 2.1 Report Description
- 2.1.1 Market Definition and Scope
- 2.2 Executive Summary
- 2.2.1 Market Snapshot, By Phases
- 2.2.2 Market Snapshot, By Study Design
- 2.2.3 Market Snapshot, By Indications/Symptoms
- 2.2.4 Market Snapshot, By Region
- 2.2.5 Opportunity Map Analysis
- 2.1 Report Description
- 3 Chapter 3
- 3.0.1 Global Clinical Trials Market Dynamics
- 3.0.2 Drivers
- 3.0.3 Restraints
- 3.0.4 Opportunities
- 3.0.5 Trends
- 3.0.6 PEST Analysis
- 3.0.7 PORTER’S Five Forces Analysis
- 4 Chapter 4
- 4.0.1 Global Clinical Trials Market Analysis, by Phases
- 4.0.2 Overview
- 4.0.3 Segment Trends
- 4.0.4 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 4.1 Phase I
- 4.1.1 Overview
- 4.1.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 4.2 Phase II
- 4.2.1 Overview
- 4.2.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 4.3 Phase III
- 4.3.1 Overview
- 4.3.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 4.3 Phase IV
- 4.3.1 Overview
- 4.3.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 5 Chapter 5
- 5.0.1 Global Clinical Trials Market Analysis, by Study Design
- 5.0.2 Overview
- 5.0.3 Segment Trends
- 5.0.4 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 5.1 Interventional trials
- 5.1.1 Overview
- 5.1.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 5.2 Observational trials
- 5.2.1 Overview
- 5.2.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 5.3 Expanded Access trials
- 5.3.1 Overview
- 5.3.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6 Chapter 6
- 6.0.1 Global Clinical Trials Market Analysis, by Indications/Symptoms
- 6.0.2 Overview
- 6.0.3 Segment Trends
- 6.0.4 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6.1 Autoimmune
- 6.1.1 Overview
- 6.1.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6.2 Blood Disorders
- 6.2.1 Overview
- 6.2.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6.3 Cancer
- 6.3.1 Overview
- 6.3.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6.4 Circulatory
- 6.4.1 Overview
- 6.4.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6.5 CNS
- 6.5.1 Overview
- 6.5.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6.6 Congenital
- 6.6.1 Overview
- 6.6.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6.7 CVS
- 6.7.1 Overview
- 6.7.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6.8 Dermatology
- 6.8.1 Overview
- 6.8.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6.9 Ear
- 6.9.1 Overview
- 6.9.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6.10 Gastrointestinal
- 6.10.1 Overview
- 6.10.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6.11 Genitourinary
- 6.11.1 Overview
- 6.11.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6.12 Infections
- 6.12.1 Overview
- 6.12.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6.13 Mental Disorders
- 6.13.1 Overview
- 6.13.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6.14 Metabolic
- 6.14.1 Overview
- 6.14.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6.15 Musculoskeletal
- 6.15.1 Overview
- 6.15.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6.16 Nose
- 6.16.1 Overview
- 6.16.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6.17 Ophthalmology
- 6.17.1 Overview
- 6.17.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6.18 Others
- 6.18.1 Overview
- 6.18.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 7 Chapter 7
- 7.0.1 Global Clinical Trials Market Analysis, by Region
- 7.0.2 Market Attractiveness Index
- 7.0.3 Overview
- 7.0.4 Regional Trends
- 7.0.5 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 7.1 Global Clinical Trials Market Analysis, by North America
- 7.1.1 Overview
- 7.1.2 Country Trends
- 7.1.3 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 7.1.4 US
- 7.1.4.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.1.5 Canada
- 7.1.5.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.2 Global Clinical Trials Market Analysis, by Europe
- 7.2.1 Overview
- 7.2.2 Country Trends
- 7.2.3 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 7.2.4 Germany
- 7.2.4.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.2.5 UK
- 7.2.5.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.2.6 France
- 7.2.6.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.2.7 Russia
- 7.2.7.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.2.8 Italy
- 7.2.8.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.2.9 Rest of Europe
- 7.2.9.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.3 Global Clinical Trials Market Analysis, by Asia Pacific
- 7.3.1 Overview
- 7.3.2 Country Trends
- 7.3.3 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 7.3.4 China
- 7.3.4.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.3.5 India
- 7.3.5.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.3.6 Japan
- 7.3.6.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.3.7 Australia
- 7.3.7.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.3.8 Rest of Asia Pacific
- 7.3.8.2 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.4 Global Clinical Trials Market Analysis, by Latin America
- 7.4.1 Overview
- 7.4.2 Country Trends
- 7.4.3 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 7.4.4 Brazil
- 7.4.4.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.4.5 Mexico
- 7.4.5.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.4.6 Rest of Latin America
- 7.4.6.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.5 Global Clinical Trials Market Analysis, by Middle East & Africa
- 7.5.1 Overview
- 7.5.2 Country Trends
- 7.5.3 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 7.5.4 GCC
- 7.5.5.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.5.5 Israel
- 7.5.5.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.5.6 South Africa
- 7.5.6.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.5.7 Rest of MEA
- 7.5.7.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8 Chapter 8
- 8.0.1 Company Profiles
- 8.1 Eli Lilly and Company
- 8.1.1 Company Overview
- 8.1.2 Product Pipeline – Phase III
- 8.1.3 Financial Overview
- 8.1.4 SWOT Analysis
- 8.1.5 Key Developments
- 8.1.6 Contact Information
- 8.2 Sun Pharmaceutical Industries Ltd.
- 8.2.1 Company Overview
- 8.2.2 Financial Overview
- 8.2.3 SWOT Analysis
- 8.2.4 Key Developments
- 8.2.5 Contact Information
- 8.3 Novo Nordisk A/S
- 8.3.1 Company Overview
- 8.3.2 Product Pipeline – Phase III
- 8.3.3 Financial Overview
- 8.3.4 Key Developments
- 8.3.5 SWOT Analysis
- 8.3.6 Contact Information
- 8.4 Pfizer Inc.
- 8.4.1 Company Overview
- 8.4.2 Product Pipeline – Phase III
- 8.4.3 Financial Overview
- 8.4.4 Key Developments
- 8.4.5 SWOT Analysis
- 8.4.6 Contact Information
- 8.5 ICON plc
- 8.5.1 Company Overview
- 8.5.2 Financial Overview
- 8.5.3 SWOT Analysis
- 8.5.4 Key Developments
- 8.5.5 Contact Information
- 8.6 Sanofi
- 8.6.1 Company Overview
- 8.6.2 Product Pipeline – Phase III
- 8.6.3 Financial Overview
- 8.6.4 SWOT Analysis
- 8.6.5 Contact Information
- 8.7 Laboratory Corporation of America Holdings
- 8.7.1 Company Overview
- 8.7.2 Financial Overview
- 8.7.3 SWOT Analysis
- 8.7.4 Key Developments
- 8.7.5 Contact Information
- 8.8 F. Hoffmann-La Roche Ltd.
- 8.8.1 Company Overview
- 8.8.2 Product Pipeline – Phase III
- 8.8.3 Financial Overview
- 8.8.4 Key Developments
- 8.8.5 SWOT Analysis
- 8.8.6 Contact Information
- 8.9 PAREXEL International Corporation
- 8.9.1 Company Overview
- 8.9.2 Financial Overview
- 8.9.3 SWOT Analysis
- 8.9.4 Key Developments
- 8.9.5 Contact Information
- 8.10 IQVIA Holdings Inc.
- 8.10.1 Company Overview
- 8.10.2 Financial Overview
- 8.10.3 Key Developments
- 8.10.4 Contact Information
- 9 Chapter 9
- 9.0.1 Research Methodology
- 9.0.2 About Us
- 1 Chapter 1
RELATED REPORTS
OUR CLIENTS
Don't just take our word. We are trusted by these great companies!
